Chief Executive Officer
Jeremy Stackawitz
Jeremy Stackawitz brings 25+ years of life sciences experience, building and scaling diagnostics companies. Most recently CEO of Senzo, a point-of-care company focused on Infectious diseases, he previously led Alba/Quotient (now AliveDx) achieving 80+ FDA approvals and major industry partnerships. Earlier, he held leadership roles at numerous Johnson & Johnson companies, in addition to working as a consultant with Monitor and McKinsey. Jeremy holds a B.A. in Biochemistry from Dartmouth College and an MBA in Healthcare Management from The Wharton School, University of Pennsylvania.
Chief Scientific Officer & Co-Founder
Adjunct Professor Alison Todd,
AM, FTSE
Dr. Alison Todd is Co-Founder of SpeeDx and one of Australia’s leading diagnostics innovators, with 100+ granted patents underpinning the company’s products and licensed technologies. She previously spent nearly 20 years at Johnson & Johnson Research before founding SpeeDx. Alison holds a BSc (Hons 1) and Ph.D. from the University of Sydney, she is a Member of the Order of Australia (AM) and Fellow of ATSE, with numerous awards including the Prime Minister’s Prize for Innovation (2022).
Chief Technology Officer & Co-Founder
Dr. Elisa Mokany
Dr. Elisa Mokany is Co-Founder of SpeeDx and leads the development of innovative diagnostic technologies, including infectious disease and antibiotic resistance tests. With 25+ years of research experience, she co-invented the PlexZymes® and PlexPrime® technologies that underpin SpeeDx’s multiplexing platform. Previously, she worked at St Vincent’s Hospital and Johnson & Johnson Research, developing cancer and leukemia diagnostics. Elisa holds a BSc (Hons 1st Class) and a PhD from UNSW, and her achievements include the Prime Minister’s Prize for Innovation (2022).
Chairman
Ingo Chakravarty
Ingo Chakravarty is an accomplished executive and board director with a proven track record in the life sciences, diagnostics, and healthcare industries. Ingo was President & CEO of Mesa Biotech, a pioneering company in rapid-PCR technology and infectious disease diagnostics. Under his leadership, Mesa Biotech was acquired by Thermo Fisher Scientific for $500M in February 2021, after which he continued as General Manager until March 2023. Prior to that, he served as President & CEO of Navican Genomics, an Intermountain Health company, where he helped advance precision medicine initiatives from 2016 to 2019.
Non-Executive Director
Bianca Ogden, MBio, PhD
Dr. Bianca Ogden brings expertise in molecular biology and healthcare investment to the SpeeDx board. She began her career researching HIV and oncology drug targets at Novartis, University College London, and Johnson & Johnson before moving into investment management. Since 2003, she has led healthcare sector investments at Platinum Asset Management, where she manages the Platinum International Health Care Fund, providing strategic insights into global healthcare markets.
Non-Executive Director
Vicki DiFrancesco
Vicki DiFrancesco is a recognized leader in the clinical laboratory industry with deep expertise in operations, commercialization, and strategic growth. She most recently served as Strategic Advisor to XiFin after leading its corporate business development strategy. Previously, she was President and CEO of Pathology Inc., acquired by LabCorp in 2016, and has held senior executive roles at Spectrum Laboratory Network, Specialty Laboratories, Quest Diagnostics, and Laboratory Corporation of America.
Non-Executive Director
Scott O'Brien
Scott O’Brien is a seasoned business leader with 25+ years of global experience in the life sciences and diagnostics industry. He has held senior roles at GenMark Diagnostics and Specific Diagnostics, where he led marketing and sales and played key roles in both companies’ successful acquisitions. Scott’s expertise in R&D, commercial strategy, and market execution—combined with his background in Microbiology from the University of Wisconsin-Madison—strengthens SpeeDx’s growth trajectory.
Non-Executive Director
Evy Douglas
Evy Douglas has deep MedTech expertise, holding several key positions at Convatec. Previously, Evy spent twenty years at Becton, Dickinson and Company where she was Senior Vice President of Corporate Development and Strategy, helping build corporate development & strategy capabilities and strengthening strategic focus and pursuing opportunities for partnerships, acquisitions and divestitures. Earlier, Evy held positions of increasing responsibility in the BD Law Group. Evy holds a Juris Doctor Degree from Harvard Law School and a bachelor’s with Honors in Political Science from Williams College, Massachusetts, U.S.
Non-Executive Director
Robert Buckley
Robert Buckley is currently Chief Financial Officer of Novanta Inc. [Nasdaq: NOVT]; joining the company in 2011. Prior to joining the Company, Mr. Buckley had a ten-year career at Revvity Inc. (formerly PerkinElmer) [NYSE: RVTY], a life science and diagnostic company selling to pharmaceutical and biotechnology markets, where he served in several financial positions of increasing responsibility. Prior to joining Revvity, Mr. Buckley held management positions with Honeywell International, Inc. [NYSE: HON], most recently in Corporate Development and Investor Relations. Mr. Buckley holds a bachelor’s degree in finance from Manhattanville College and an Master of Business Administration degree from University of California Los Angeles (U.C.L.A.) Anderson School of Management.
The SpeeDx leadership team combines scientific innovation with operational and commercial experience. Our co-founders, Adj. Prof. Alison Todd and Dr. Elisa Mokany, are among Australia's most decorated scientists, holding over 100 patents and pioneering multiplexing technologies that advance modern molecular diagnostics. Their innovations earned Australia's highest recognition: the Prime Minister's Prize for Innovation (2022), alongside prestigious honors including the Clunies Ross Award for Innovation and induction into the Australian Academy of Technology and Engineering (2020). Individually, Adj. Prof. Alison Todd received the Order of Australia (AM) in 2023, being recognized for her exceptional lifetime contributions to both medical research and education, and Dr. Elisa Mokany was awarded the Outstanding Achievement Medtech Industry Award in 2017.
Our executive and board leadership brings decades of scientific, partnering, and commercial success in the global diagnostics industry. From leading companies through successful listings and strategic acquisitions, to building global medical technology businesses, our team has repeatedly demonstrated the ability to scale innovation into sustained business and commercial success.
Together, this leadership combines deep technical expertise rooted in molecular diagnostics with the strategic vision and operational experience to deliver molecular solutions that enable better decisions.
Meet the team
